1-8 of 8
Xavier Thomas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term real world evidence of CPX-351 of high-risk AML patients identified high rate of negative MRD and prolonged OS

Thomas Cluzeau, Fabio Guolo, Edmond Chiche, Paola Minetto, Ramy Rahmé, Sarah Bertoli, Luana Fianchi, Jean-Baptiste Micol, Michele Gottardi, Pierre Peterlin, Sara Galimberti, Xavier Thomas, Giuliana Rizzuto, Olivier Legrand, Michela Rondoni, Emmanuel Raffoux, Giambattista Bertani, Alexis Leon Caulier, Michelina Dargenio, Caroline Bonmati, Atto Billio, Caroline Lejeune, Barbara Scappini, Arnaud Pigneux, Patrizia Zappasodi, Christian Récher, Francesco Grimaldi, Lionel Adès, Roberto Massimo Lemoli
Journal: Blood Advances
Blood Adv bloodadvances.2024014279.
https://doi.org/10.1182/bloodadvances.2024014279
Published: 2024
Journal Articles

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial

Clinical Trials & Observations
Gail J. Roboz, Guillermo Sanz, Elizabeth A. Griffiths, Karen Yee, Hagop Kantarjian, Christian Récher, Michael T. Byrne, Elżbieta Patkowska, Hee-Je Kim, Xavier Thomas, Ine Moors, Wendy Stock, Árpád Illés, Pierre Fenaux, Yasushi Miyazaki, Takahiro Yamauchi, Casey L. O'Connell, Yong Hao, Harold N. Keer, Mohammad Azab, Hartmut Döhner
Journal: Blood Advances
Blood Adv (2024) 8 (8): 2020–2029.
https://doi.org/10.1182/bloodadvances.2023012062
Published: 2024
Includes: Supplemental data
Journal Articles

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3 -mutated AML: a phase 3b trial

Clinical Trials & Observations
Jorge Sierra, Pau Montesinos, Xavier Thomas, Laimonas Griskevicius, Thomas Cluzeau, Denis Caillot, Ollivier Legrand, Clara Minotti, Mario Luppi, Firas Farkas, Bourras-Rezki Bengoudifa, Geralyn Gilotti, Sejla Hodzic, Alessandro Rambaldi, Adriano Venditti
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6441–6450.
https://doi.org/10.1182/bloodadvances.2023009847
Published: 2023
Includes: Supplemental data
Journal Articles

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

Clinical Trials & Observations
Pierre Fenaux, Marco Gobbi, Patricia L. Kropf, Jean-Pierre J. Issa, Gail J. Roboz, Jiri Mayer, Jürgen Krauter, Tadeusz Robak, Hagop Kantarjian, Jan Novak, Wieslaw. W. Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph Brandwein, Liana Gercheva-Kyuchukova, Judit Demeter, Elizabeth Griffiths, Karen Yee, Konstanze Döhner, Yong Hao, Harold Keer, Mohammad Azab, Hartmut Döhner
Journal: Blood Advances
Blood Adv (2023) 7 (17): 5027–5037.
https://doi.org/10.1182/bloodadvances.2023010179
Published: 2023
Includes: Supplemental data
Journal Articles

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1 -mutated AML

Clinical Trials & Observations
Stéphane de Botton, Pierre Fenaux, Karen Yee, Christian Récher, Andrew H. Wei, Pau Montesinos, David C. Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Montserrat Arnan, William Blum, Daniela Cilloni, Devendra K. Hiwase, Joseph G. Jurcic, Jürgen Krauter, Xavier Thomas, Justin M. Watts, Jay Yang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Emma Barrett, Jorge Cortes
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3117–3127.
https://doi.org/10.1182/bloodadvances.2022009411
Published: 2023
Includes: Supplemental data
Journal Articles

Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML

Clinical Trials & Observations
Juliette Lambert, Jerome Lambert, Xavier Thomas, Alice Marceau-Renaut, Jean-Baptiste Micol, Aline Renneville, Emmanuelle Clappier, Sandrine Hayette, Christian Récher, Emmanuel Raffoux, Arnaud Pigneux, Celine Berthon, Christine Terré, Karine Celli-Lebras, Sylvie Castaigne, Nicolas Boissel, Philippe Rousselot, Claude Preudhomme, Hervé Dombret, Nicolas Duployez
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5258–5268.
https://doi.org/10.1182/bloodadvances.2021004322
Published: 2021
Includes: Supplemental data
Journal Articles

Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort

Clinical Trials & Observations
Edmond Chiche, Ramy Rahmé, Sarah Bertoli, Pierre-Yves Dumas, Jean-Baptiste Micol, Yosr Hicheri, Florence Pasquier, Pierre Peterlin, Patrice Chevallier, Xavier Thomas, Michael Loschi, Alexis Genthon, Ollivier Legrand, Mohamad Mohty, Emmanuel Raffoux, Patrick Auberger, Alexis Caulier, Magalie Joris, Caroline Bonmati, Gabrielle Roth-Guepin, Caroline Lejeune, Arnaud Pigneux, Norbert Vey, Christian Recher, Lionel Ades, Thomas Cluzeau
Journal: Blood Advances
Blood Adv (2021) 5 (1): 176–184.
https://doi.org/10.1182/bloodadvances.2020003159
Published: 2021
Includes: Supplemental data
Journal Articles

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Clinical Trials & Observations
Claude Gardin, Cécile Pautas, Elise Fournier, Raphaël Itzykson, Emilie Lemasle, Jean-Henri Bourhis, Lionel Adès, Jean-Pierre Marolleau, Jean-Valère Malfuson, Lauris Gastaud, Emmanuel Raffoux, Juliette Lambert, Thorsten Braun, Xavier Thomas, Sylvain Chantepie, Thomas Cluzeau, Stéphane de Botton, Céline Berthon, Nicolas Boissel, Nicolas Duployez, Christine Terré, Régis Peffault de Latour, Mauricette Michallet, Karine Celli-Lebras, Claude Preudhomme, Hervé Dombret
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1942–1949.
https://doi.org/10.1182/bloodadvances.2019001349
Published: 2020
Includes: Supplemental data